Ipsen announces weekly share buy-back transactions under MAR
Between June 8 and 12, 2026, Ipsen repurchased 13,712 shares at a weighted average price of €156.73 per share.
See the latest news and media coverage for Ipsen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global specialty biopharmaceutical company
ipsen.comLast updated
In short: Ipsen achieved strong double-digit growth in 2025, secured key EU approvals for Ojemda, and expanded its pipeline through strategic R&D partnerships.
Between June 8 and 12, 2026, Ipsen repurchased 13,712 shares at a weighted average price of €156.73 per share.
The assessment confirms challenges in generating comparative evidence for this rare tumor, and Ojemda is the first approved targeted therapy in this setting.
The report details progress in strategy, partnerships, pipeline, and sustainability, highlighting impact for patients.
Late-breaking results show fatigue improvements and ALP normalization in real-world studies, reinforcing IQIRVO's efficacy.
Following its quarterly review of the CAC 40 family indices, Euronext announces the inclusion of pharmaceutical companies Abivax and Ipsen, as well as the...
IPSEN (OTCMKTS:IPSEY – Free Report) – Equities researchers at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for IPSEN in a report issued...
226C0788 FR0010259150-FS0497-DER02 June 5, 2026 Declaration of crossing of thresholds and declaration of intention...
(Boursier.com) — The Alasol Foundation, based in Luxembourg, declared having crossed upwards, on May 28, 2026, the thresholds of 5%, 10%, 15%, 20...
Track Ipsen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ipsen and other trending companies.